

Human Whole Exome Sequencing

1. Sample Requirements

| Sample Type | Amount (Qubit®) | Volume | Concentration | Purity (NanoDrop™) |
|---------------------------|-----------------|---------|---------------|---|
| Genomic DNA | ≥ 400 ng | ≥ 20 µL | ≥ 20 ng/µL | OD260/280=1.8-2.0; no degradation, no contamination |
| cfDNA/ctDNA | ≥ 50 µg | - | - | Fragments should be in multiples of 170 bp, no genomic contamination |
| Genomic DNA from *FFPE | ≥ 800ng | - | - | Fragments should be longer than 1000 bp |

*FFPE: Formalin-fixed-paraffin-embedded

2. Sequencing Parameters

| | |
|-------------------------------------|--|
| Platform | ILLUMINA NovaSeq 6000 |
| Read length | Paired-end 150 bp |
| Recommended sequencing depth | For Mendelian disorder/rare disease: effective sequencing depth above 50× (6 G); For tumor sample: effective sequencing depth above 100× (12 G) |
| Data quality | Guaranteed ≥ 80% bases with Q30 or higher |
| **Turnaround time | 22 working days from verification of sample quality to data releasing without bioinformatic analysis |

**Turnaround time varies depending on the project volume.

3. Data Analysis Contents

| Standard Analysis |
|---|
| Data quality control: filtering reads containing adapter or with low quality |
| Alignment with reference, statistics of sequencing depth and coverage |
| SNP and InDel calling, annotation and statistics |
| Somatic variant detection (only apply for tumor-normal paired samples) SNP calling, annotation and statistics InDel calling, annotation and statistics CNV calling, annotation and statistics |

| | | Methods |
|---------------------------------------|------------------------------|--|
| Advanced analysis | Cancer | Screening for Predisposing Genes (feasible if only normal samples are provided) |
| | | Mutational Spectrum & Mutational Signature |
| | Driver gene analysis | Identification of Known Driver Genes |
| | | Significantly Mutated Gene & Pathway Analysis |
| | | Mutation Relation Test of Significantly Mutated Genes |
| | | Identification of Driver Genes Based on Mutation Clustering Bias |
| | | Identification of Driver Somatic CNVs |
| | | Mutation Site Displaying |
| | Tumor heterogeneity analysis | Tumor Purity & Ploidy Estimation |
| | | Intra-tumor Heterogeneity Analysis |
| | | Tumor Evolution Analysis (One normal and at least 3 tumor samples from the same patient are needed) |
| | | Tumor Neoantigen Identification |
| | Monogenic disease | Candidate Variant Filtration |
| | | Analysis under dominant / recessive model |
| | | Linkage Analysis |
| | | Region of Homozygosity Analysis (ROH) |
| | Polygenic disease | Candidate Variant Filtration |
| | | Analysis under dominant / recessive model |
| Linkage Analysis | | |
| Region of Homozygosity Analysis (ROH) | | |
| De novo SNV/InDel Analysis | | |